Clinical Trials Logo

Filter by:
NCT ID: NCT00874926 Completed - Hemophilia A Clinical Trials

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Start date: June 2008
Phase: N/A
Study type: Observational

The aim of this international prospective, non-interventional post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer in treatment of patients with haemophilia A under daily-life treatment conditions.

NCT ID: NCT00543439 Completed - Hemophilia A Clinical Trials

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Start date: December 2007
Phase: Phase 3
Study type: Interventional

The purpose of this research study is to determine the effectiveness, safety, and pharmacokinetics (PK) of moroctocog alfa (AF-CC) in previously treated subjects, who are younger than 6 years of age, with severe or moderately severe hemophilia A.

NCT ID: NCT00477373 Completed - Bipolar Disorder Clinical Trials

Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study

GEVANS
Start date: December 2006
Phase: Phase 4
Study type: Interventional

To assess the efficacy of Di-valproate in Bipolar I patients suffering from a manic episode according to DSM IV (APA 1994) over a 12 weeks period of treatment. To evaluate the clinical safety of Di-valproate.

NCT ID: NCT00171301 Completed - Iron Overload Clinical Trials

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

ESCALATOR
Start date: June 2005
Phase: Phase 4
Study type: Interventional

To allow patients treated with deferasirox in the core study to continue iron chelation therapy for 2 years or until the drug became locally commercially available. To evaluate the long-term safety and efficacy of deferasirox by measuring treatment success, change in liver iron content (LIC) and change in serum ferritin levels. Safety was mainly assessed by incidence of adverse events (AEs)and clinically significant lab parameters.

NCT ID: NCT00171171 Completed - Beta-Thalassemia Clinical Trials

A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

Start date: May 2004
Phase: Phase 3
Study type: Interventional

Because patients with beta-thalassemia are unable to actively eliminate iron from the body, toxic and eventually lethal levels of iron can accumulate as a result of repeated blood transfusions. This study will evaluate the efficacy, safety and tolerability of deferasirox.